• Documented paroxysmal, persistent, or permanent non-valvular AF (documentation must include an electrocardiogram, Holter, or event recorder)

• At high risk of stroke or systemic embolism, defined as a CHA2DS2-VASc score of ≥ 2 for men and ≥ 3 for women

• Eligible for long-term NOAC therapy

• Able to comply with the required NOAC medication regimen if randomized to the Control Group

• Able to comply with the required medication regimen post-device implant if subject is randomized to the Device Group or subject is a Roll-in

• Able to understand, and is willing to provide, written informed consent to participate in the trial, prior to any clinical investigation related procedure or assessment

• 18 years of age or older, or the age of legal consent

• Able and willing to return for required follow-up visits and assessments